Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 June 2025 | Story Leonie Bolleurs | Photo Supplied
Anita Venter
According to Dr Anita Venter, eco-bricks help prevent further environmental degradation, a theme often highlighted by World Environment Day.

Students filling plastic bottles with tightly packed wrappers, chips packets, and cling wrap until they are sturdy may not look like revolutionaries, but that is exactly what they are. This Eco-Bricks initiative is a grassroots effort that transforms plastic waste into construction material, sparking environmental change from the ground up. From there, the possibilities multiply – from benches to buildings, and from awareness to action.

It is not just about just stuffing bottles; it is about shifting mindsets.

Dr Anita Venter, Lecturer in the Centre for Development Support at the University of the Free State (UFS), believes eco-bricks directly address the urgent need for solutions to plastic pollution. “By taking plastic out of the waste stream and giving it a new, useful life, we're actively participating in ecosystem restoration and preventing further environmental degradation, a theme often highlighted by World Environment Day.”

However, the Eco-Bricks project is doing more than managing waste. “Beyond this practical application, it serves as a powerful community development tool, empowering individuals to take control of waste management and fostering a vital environmental consciousness.”

And while we can dream of a plastic-free world, Dr Venter is grounded in today’s realities. “So, my approach is that I'd rather have plastic contained safely within a bottle – repurposed in a regenerative way – than seeing it break down into nano-plastics, poisoning our earth. This project is about finding practical solutions within our current reality.”

 

A no-cost solution 

Dr Venter does not lead from a podium; she is mentoring from the sidelines. “I'm primarily involved in mentoring our student champions. They are the real drivers, facilitating the eco-brick training peer-to-peer. It's about empowering them to spread the knowledge and skills, rather than me being the sole instructor. It’s a beautiful ripple effect.”

And ripple it does. “These initiatives continue in their communities, and that truly warms my heart,” she says. The students are taking the lessons home, creating a chain reaction of action and awareness. “It’s not just about building bricks; it’s about inspiring continued action.”

The concept’s biggest success story? Thousands of eco-bricks being used by the Natural Building Collective in the Western Cape for formalised buildings. Proof that what was started by students can reshape entire landscapes.

“I see eco-bricks as an incredible community development tool. What’s beautiful about it is that it’s a no-cost activity. Anyone who wants to start a community development initiative can pick it up, and they immediately reap the dual benefits of cleaning their environment and taking control of their own waste management. It’s very empowering on a grassroots level.”

 

Regeneration starts here

Dr Venter, who has been part of the initiative since 2013, sees it as integral to her broader environmental work as climate activist focusing on research related to housing, informal settlement upgrading, culture, socio-ecological development, regenerative design, and art. She is quick to connect plastic pollution to the deeper ecological crisis we face. “Plastic is a monumental environmental problem, rapidly leading to biodiversity collapse, which I honestly believe is a far more pressing issue than even the climate crisis itself. It’s stark – babies are now born with plastic in their tiny bodies, and these microplastics are found in every human organ. It’s a pervasive crisis.” 

With students and community leaders now steering the project, she is hopeful about the future: “The beauty of something so accessible and practical is that it doesn’t need top-down direction; it flourishes from the ground up as people recognise its value and adopt it.”

Dr Venter’s commitment to making waste meaningful goes well beyond the Eco-Bricks initiative. In the project What Remains Through Time, Slowness and Stillness, waste is transformed into meaningful art, and communities step into the role of co-creators. 

Using post-natural building techniques, the project incorporates both waste and natural materials, marrying ecological restoration with social transformation. Sites such as the Oliewenhuis Art Museum, Bloemfontein National Hospital, and Sekoele Holistic Living Arts Centre serve as hubs where participants can engage hands-on, learning new skills while strengthening their communities.

According to Dr Venter, the main activities at Oliewenhuis are from June to September this year. Here, the focus is on community collaboration and regenerative art that goes far beyond constructing physical spaces. “We’re aiming to break down social barriers and make art truly accessible and inclusive within public spaces. It’s as much about building community as it is about building structures,” she says.

So, what can you do?

Start where you are. Join an eco-brick or art-for-regeneration initiative. “Go beyond sustainability! We need to regenerate, to ‘renew, restore, revitalise’,” says Dr Venter. Attend a training event. Share what you learn. “That’s how we create real, lasting change – through shared knowledge and empowered action.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept